Astrazeneca (AZN) Cost of Revenue (2009 - 2026)

Astrazeneca (AZN) has reported Cost of Revenue for 18 consecutive years, with $2.7 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Cost of Revenue rose 19.5% year-over-year to $2.7 billion; the TTM figure through Mar 2026 stood at $11.1 billion (up 8.21% YoY), while the FY2025 annual figure was $10.6 billion, up 4.17% from the prior year.
• Cost of Revenue came in at $2.7 billion for Q1 2026 at Astrazeneca, down from $3.1 billion in the prior quarter.
• The five-year high for Cost of Revenue was $3.5 billion in Q1 2022, with the low at $1.9 billion in Q1 2023.
• Average Cost of Revenue over 5 years is $2.6 billion, with a median of $2.7 billion recorded in 2026.
• Across the five-year window, Cost of Revenue surged 138.4% in 2022 and sank 45.74% in 2023, its largest moves.
• Year by year, Cost of Revenue stood at $2.9 billion in 2022, then dropped by 20.41% to $2.3 billion in 2023, then increased by 18.07% to $2.7 billion in 2024, then advanced by 14.42% to $3.1 billion in 2025, then decreased by 14.11% to $2.7 billion in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $2.7 billion, $3.1 billion, and $2.8 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.